Synairgen (LON:SNG) Hits New 52-Week Low – Here’s What Happened

Shares of Synairgen plc (LON:SNG) reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 1.71 ($0.02) and last traded at GBX 2.12 ($0.03), with a volume of 669799 shares trading hands. The stock had previously closed at GBX 2.06 ($0.03).

Synairgen Stock Performance

The firm has a market cap of £4.27 million, a price-to-earnings ratio of -70.67 and a beta of -2.23. The stock has a 50 day moving average of GBX 3.06 and a 200 day moving average of GBX 3.75. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).